-
EP3704118
European procedure
Extract from the Register of European Patents
EP About this file: EP3704118
| EP3704118 - AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 18.11.2022 Database last updated on 01.04.2026 | |
| Former | The patent has been granted Status updated on 10.12.2021 | ||
| Former | Grant of patent is intended Status updated on 20.07.2021 | ||
| Former | Request for examination was made Status updated on 07.08.2020 | ||
| Former | The international publication has been made Status updated on 11.05.2019 | ||
| Former | unknown Status updated on 29.11.2018 | Most recent event Tooltip | 18.11.2022 | No opposition filed within time limit | published on 21.12.2022 [2022/51] | Applicant(s) | For all designated states Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US | [2020/37] | Inventor(s) | 01 /
MERTZMAN, Michael E. c/o Bristol-Myers Squibb Company Route 206&Province Line Road Princeton New Jersey 08543 / US | 02 /
DZIERBA, Carolyn Diane c/o Bristol-Myers Squibb Company 100 Binney Street Cambridge MA 02142 / US | 03 /
GUERNON, Jason M. c/o Bristol-Myers Squibb Company Route 206&Province Line Road Princeton New Jersey 08543 / US | 04 /
HART, Amy C. c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton New Jersey 08543 / US | 05 /
LUO, Guanglin c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton New Jersey 08543 / US | 06 /
MACOR, John E. c/o Sanofi 153 2nd Avenue Waltham Massachusetts 02451 / US | 07 /
PITTS, William J. c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton New Jersey 08643 / US | 08 /
SHI, Jianliang c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton New Jersey 08543 / US | 09 /
SPERGEL, Steven H. c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton New Jersey 08543 / US | [2020/37] | Representative(s) | Dehns 10 Old Bailey London EC4M 7NG / GB | [N/P] |
| Former [2020/37] | Dehns St. Bride's House 10 Salisbury Square London EC4Y 8JD / GB | Application number, filing date | 18804177.6 | 29.10.2018 | [2020/37] | WO2018US57968 | Priority number, date | US201762578607P | 30.10.2017 Original published format: US 201762578607 P | US201862626853P | 06.02.2018 Original published format: US 201862626853 P | [2020/37] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019089442 | Date: | 09.05.2019 | Language: | EN | [2019/19] | Type: | A1 Application with search report | No.: | EP3704118 | Date: | 09.09.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.05.2019 takes the place of the publication of the European patent application. | [2020/37] | Type: | B1 Patent specification | No.: | EP3704118 | Date: | 12.01.2022 | Language: | EN | [2022/02] | Search report(s) | International search report - published on: | EP | 09.05.2019 | Classification | IPC: | C07D471/04, C07F9/60, A61P29/00, A61K31/5025 | [2021/31] | CPC: |
A61P29/00 (EP,IL,KR);
C07D471/04 (EP,IL);
C07D487/04 (IL,KR,US);
A61K31/5025 (IL,KR);
A61P1/00 (IL,KR);
A61P17/06 (IL,KR);
|
| Former IPC [2020/37] | C07D471/04, C07F9/09, A61P29/00, A61K31/5025 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/37] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | AMINOIMIDAZOPYRIDAZINE ALS KINASEINHIBITOREN | [2020/37] | English: | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | [2020/37] | French: | AMINOIMIDAZOPYRIDAZINES EN TANT QU'INHIBITEURS DE KINASE | [2020/37] | Entry into regional phase | 26.05.2020 | National basic fee paid | 26.05.2020 | Designation fee(s) paid | 26.05.2020 | Examination fee paid | Examination procedure | 26.05.2020 | Examination requested [2020/37] | 26.05.2020 | Date on which the examining division has become responsible | 14.12.2020 | Amendment by applicant (claims and/or description) | 21.07.2021 | Communication of intention to grant the patent | 30.11.2021 | Fee for grant paid | 30.11.2021 | Fee for publishing/printing paid | 30.11.2021 | Receipt of the translation of the claim(s) | Opposition(s) | 13.10.2022 | No opposition filed within time limit [2022/51] | Fees paid | Renewal fee | 14.10.2020 | Renewal fee patent year 03 | 19.10.2021 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [AP] WO2018148626 (BRISTOL MYERS SQUIBB CO et al.) | [AD] US2009163489 (BOOKER SHON et al.) | [A] PHILIP A. HARRIS ET AL: "Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 4, 10 February 2017 (2017-02-10), pages 1247 - 1261, XP055448328, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b01751 DOI: http://dx.doi.org/10.1021/acs.jmedchem.6b01751 | [A] PHILIP A. HARRIS ET AL: "Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis", ACS MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 12, 12 December 2013 (2013-12-12), pages 1238 - 1243, XP055123759, ISSN: 1948-5875, DOI: 10.1021/ml400382p DOI: http://dx.doi.org/10.1021/ml400382p | by applicant | US2015322111 | US201762458144 | US2009163489 | KROEMER ET AL., CELL DEATH DIFFER, vol. 16, 2009, pages 3 - 11 | GOLSTEIN P; KROEMER G, TRENDS BIOCHEM. SCI., vol. 32, 2007, pages 37 - 43 | FESTJENS ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1757, 2006, pages 1371 - 1387 | HOLLER ET AL., NAT. IMMUNOL., vol. 1, 2000, pages 489 - 495 | DEGTEREV ET AL., NAT. CHEM. BIOL., vol. 4, 2008, pages 313 - 321 | DEGTEREV ET AL., NAT CHEM BIOL, vol. 1, 2005, pages 112 - 119 | HE ET AL., CELL, vol. 137, 2009, pages 1100 - 1111 | CHO, CELL, vol. 137, 2009, pages 1112 - 1123 | ZHANG ET AL., SCIENCE, vol. 325, 2009, pages 332 - 336 | TRICHONAS ET AL., PROC. NATL. ACAD. SCI., vol. 107, 2010, pages 21695 - 21700 | LIN ET AL., CELL REP., vol. 3, 2013, pages 200 - 210 | CHO ET AL., CELL, vol. 137, 2009, pages 1112 - 1123 | DUPREZ ET AL., IMMUNITY, vol. 35, 2011, pages 908 - 918 | ROYCHOWDHURY ET AL., HEPATOLOGY, vol. 57, pages 1773 - 1783 | VANDENABEELE ET AL., NATURE, vol. 10, 2010, pages 700 - 714 | VANDENABEELE ET AL., SCI. SIGNALLING, vol. 3, 2010, pages 1 - 8 | ZHANG ET AL., CELLULAR & MOL. IMMUNOLOGY, vol. 7, 2010, pages 243 - 249 | MORIWAKI ET AL., GENES DEV, vol. 27, 2013, pages 1640 - 1649 | ITO ET AL., SCIENCE, vol. 353, 2016, pages 603 - 608 | VITNER ET AL., NATURE MED, vol. 20, 2014, pages 204 - 208 | "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY | "Design of Prodrugs", 1985, ELSEVIER | "Methods in Enzymology", vol. 112, 1985, ACADEMIC PRESS, pages: 309 - 396 | H. BUNDGAARD: "A Textbook of Drug Design and Development", 1991, article "Design and Application of Prodrugs", pages: 113 - 191 | H. BUNDGAARD, ADVANCED DRUG DELIVERY REVIEWS, vol. 8, 1992, pages 1 - 38 | "Remington's Pharmaceutical Sciences", 1985 | MAFFRAND, J. P. ET AL., HETEROCYCLES, vol. 16, no. l, 1981, pages 35 - 7 | TETRAHEDRON, vol. 61, 2005, pages 10827 - 10852 | MIYAURA, N.; SUZUKI, A., CHEMICAL REVIEWS, vol. 95, 1995, pages 2457 - 2483 | WILLIAMSON, A. JUSTUS LIEBIGS, ANN. CHEM, vol. 77, pages 37 - 49 | WAMY, K.C.K. ET AL., CHEM. REV., vol. 109, 2009, pages 2551 - 2651 |